ArticleBMC cancer2025
Biomimetic cancer cell membrane engineered lipid nanoparticles for enhanced chemotherapy of homologous malignant tumor.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Engineering Biomimetic Nanoparticle Performance Through Fabrication Method Selection: Turbulent Jet Mixing, Microfluidics, and Extrusion.Small methods · 2026Article
- The Mechanism and Application of Traditional Chinese Medicine Nano-Formulations in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026Review
- Macrophage-based therapeutic strategies in glioblastoma: advancements in drug delivery and immunotherapy.Frontiers in oncology · 2026Review
- Biomimetic nanoparticles in cancer photodynamic therapy: a review of targeted delivery systems and therapeutic outcomes.Beilstein journal of nanotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe advancement of biomimetic drug delivery systems designed for biomedical applications has attracted considerable attention from researchers in recent years. A particularly noteworthy approach involves the use of various cell membranes, which can impart distinctive functionalities to the nanoparticles, including specific recognition of target cells, prolonged circulation within the bloodstream, and enhanced ability to evade the immune system, as surface coatings on nanoparticles. This innovative strategy has positioned cell membrane-coated nanoparticles (CMCNPs) as a promising framework for addressing a wide range of diseases more effectively.
methodsIn the current investigation, lipid nanoparticles were specifically engineered using glioblastoma cell membrane (GBMM) coatings, termed as LNPs/D@GBMM, to serve as targeted nanotheranostics against homologous malignant glioblastoma (GBM). The physicochemical properties of LNPs/D@GBMM were investigated in terms of particle size, morphology, drug loading (DL), drug release behavior and so on. Homologous cellular uptake was evaluated by confocal laser scanning microscopy (CLSM). Cell cytotoxicity was evaluated by MTT assay. Moreover, the bio-distribution of CMCNPs in vivo was investigated via the near-infrared (NIR) fluorescence imaging technique, and the anti-tumor effect in vivo was evaluated in xenografted nude mice.
resultsCompared to non-targeted lipid nanoparticles, LNPs/D@GBMM exhibited superior cytotoxic effects against homologous tumor cells. In addition, fluorescence imaging of targeted tumor cells treated with LNPs/D@GBMM indicated a marked increase in cell internalization, and improved fluorescence distribution in vivo. LNPs/D@GBMM finally produced an excellent tumor suppression effect on homologous tumors.
conclusionThe robust platform established by CMCNPs leveraging the inherent characteristics of homologous tumor cell membranes, is expected to facilitate systemic delivery of therapeutic agents specifically aimed at treating tumors, thus advancing the efficacy of cancer therapy in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.